Heartflow (HTFL) Research & Development (2024 - 2025)
Heartflow's quarterly Research & Development came in at $18.7 million in Q4 2025, up 52.01% year-on-year from $12.3 million in Q4 2024, and up 7.91% quarter-over-quarter from $17.3 million in Q3 2025.
Heartflow has reported Research & Development for 2 years, with the latest figure at $18.7 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 52.01% year-over-year to $18.7 million; the trailing twelve-month figure through Dec 2025 stood at $63.3 million (changed N/A YoY), and the FY2025 full-year result was $64.9 million, up 49.18% from the prior year.
- Research & Development for Q4 2025 stood at $18.7 million, up from $17.3 million in the prior quarter.
- The five-year high for Research & Development was $18.7 million in Q4 2025, with the low at $9.9 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | 198.79 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | - |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | 67.77 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 30.34 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | 39.11 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | 18.37 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | 56.85 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | 21.52 Mn |
| 10 | Heartflow | 1.15 Bn | 974.90 Mn | 39.06 Mn | 18.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.67 Mn |
| Sep 30, 2025 | 17.30 Mn |
| Jun 30, 2025 | 15.03 Mn |
| Dec 31, 2024 | 12.28 Mn |
| Sep 30, 2024 | 11.86 Mn |
| Jun 30, 2024 | 9.93 Mn |